| 周 璇,廖盼丽,吴文英,姜 辉,江 华.西黄胶囊联合GP方案对中晚期乳腺癌患者血清TNF-α，VEGF，MMP-2，MMP-9水平的影响[J].现代生物医学进展英文版,2017,17(23):4525-4528. |
| 西黄胶囊联合GP方案对中晚期乳腺癌患者血清TNF-α，VEGF，MMP-2，MMP-9水平的影响 |
| Effect of Xihuang Capsule Combined with GP Regimen on Serum Levels of TNF-α, VEGF, MMP-2 and MMP-9 of Patients with Advanced Breast Cancer |
| Received:December 30, 2016 Revised:January 26, 2017 |
| DOI：10.13241/j.cnki.pmb.2017.23.029 |
| 中文关键词: 西黄胶囊 GP方案 乳腺癌 血管内皮细胞生长因子 基质金属蛋白酶-2 基质金属蛋白酶-9 |
| 英文关键词: Xihuang capsule GP regimen Breast cancer Vascular endothelial growth factor Matrix metalloproteinase -2 Matrix metalloproteinase -9 |
| 基金项目:湖北省科技计划项目(2012FFA071） |
|
| Hits: 306 |
| Download times: 205 |
| 中文摘要: |
| 摘要 目的：研究西黄胶囊联合GP方案对中晚期乳腺癌患者血清肿瘤坏死因子-α(TNF-α)、人血管内皮细胞生长因子(VEGF)、基质金属蛋白酶-2(MMP-2)、基质金属蛋白酶-9(MMP-9)的影响。方法：入选2014年3月至2015年2月我院收治的88例中晚期乳腺癌患者，按照患者入院顺序分为观察组和对照组，44例每组。对照组使用GP方案进行治疗，观察采取西黄胶囊联合GP方案进行治疗。比较两组患者治疗前后血清TNF-α、VEGF、MMP-2、MMP-9水平的变化、临床疗效和不良反应的发生情况。结果：观察组的总有效率显著高于对照组[84.09%(37/44) vs 50.00%(22/44)](P<0.05)。治疗前，两组患者血清TNF-α、VEGF、MMP-2、MMP-9水平比较差异无统计学意义(P>0.05)；治疗后，两组患者的血清TNF-α、VEGF、MMP-2、MMP-9水平均较治疗前显著降低(P<0.05)，观察组的血清TNF-α、VEGF、MMP-2、MMP-9水平均明显低于对照组(P<0.05)。两组患者恶心呕吐等不良反应率比较差异无统计学意义(P>0.05)，观察组脱发、腹泻、肝功能异常、食欲下降、贫血、白细胞下降发生率明显低于对照组(P<0.05)。结论：西黄胶囊联合GP方案较单用GP方案能更有效降低中晚期乳腺癌患者血清TNF-α、VEGF、MMP-2、MMP-9水平，临床疗效更好，安全性更高。 |
| 英文摘要: |
| ABSTRACT Objective: To study the effect of Xihuang Capsule combined with GP regimen on the serum levels of tumor necrosis factor-α(TNF-α), vascular endothelial growth factor(VEGF), matrix metalloproteinase-2 (MMP-2) and matrix metalloproteinase-9 (MMP-9) of patients with advanced breast cancer. Methods: 88 patients with advanced breast cancer admitted in our hospital from March 2014 to February 2015 were selected and divided into the observation group and the control group according to the order of admission. The control group was treated by the GP program, the observation group was given Xihuang capsule combined with GP regimen. The serum levels of TNF-α, VEGF, MMP-2 and MMP-9 in the two groups were compared before and after treatment. The clinical efficacy and incidence of side effects were analyzed. Results: The total effective rate of observation group was significantly higher than that of the control group [84.09% (37/44) vs 50.00% (22/44)] (P<0.05). There was no significant difference in the serum levels of TNF-α, VEGF, MMP-2 and MMP-9 between the two groups before treatment (P>0.05). After treatment, the serum TNF-α, VEGF, MMP-2 and MMP-9 levels were significantly lower than those before treatment(P<0.05). The serum levels of TNF-α, VEGF, MMP-2 and MMP-9 of obser- vation group were significantly lower than those of the control group (P<0.05). There was no significant difference in the incidence rate of nausea and vomiting between the two groups (P>0.05). The incidence of alopecia, diarrhea, abnormal liver function, decreased appe- tite, anemia and leukopenia in the observation group were significantly lower than those of the control group (P<0.05). Conclusion: Xihuang Capsule combined with GP regimen could more effectively reduce the levels of serum TNF-α, VEGF, MMP-2 and MMP-9 of patients with advanced breast cancer than GP regime alone with higher safety. |
|
View Full Text
View/Add Comment Download reader |
| Close |
